BMJ: 2019 Research on the effectiveness of the drug treatment for new coronary pneumonia.

Recently, researchers conducted a systematic review and meta-analysis to examine the therapeutic effects of covid-19 in 2019.
researchers looked at the U.S. Centers for Disease Control and Prevention's COVID-19 research database, which includes 25 electronic databases and six Chinese databases, as of July 20, 2020.
selection criteria were randomized clinical trials that randomized patients with suspected, possible, or confirmed covid-19 patients into drug treatment groups, standard care groups, or placebo groups. a total of 23 randomized controlled trials were included in this meta-analysis
.
most of the evidence has very low credibility due to bias and serious data inaccuracy.
compared to standard care and mechanical ventilation, glucocorticoids are the only drug interventions that have evidence of reducing patient mortality.
, three drugs may shorten the duration of a patient's symptoms compared to standard treatment, namely hydroxychloroquine (average difference of -4.5 days, low certainty), Redsiwe (-2.6 days, medium certainty) and Crez (Lopinavir/Litonevir) (low certainty, 1.2 days).
hydroxychloroquine may increase the risk of adverse events compared to other interventions, while Redsiwe has a lower risk of adverse reactions to discontinuation.
study suggests that glucocorticoids may reduce mortality and mechanical ventilation risk in patients with covid-19 compared to standard care.
the effectiveness of most interventions is uncertain.
.